Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study Journal Article


Authors: Flory, A.; Kruglyak, K. M.; Tynan, J. A.; McLennan, L. M.; Rafalko, J. M.; Fiaux, P. C.; Hernandez, G. E.; Marass, F.; Nakashe, P.; Ruiz-Perez, C. A.; Fath, D. M.; Jennings, T.; Motalli-Pepio, R.; Wotrang, K.; McCleary-Wheeler, A. L.; Lana, S.; Phillips, B.; Flesner, B. K.; Leibman, N. F.; LaDue, T.; Tripp, C. D.; Coomber, B. L.; Woods, J. P.; Miller, M.; Aiken, S. W.; Wolf-Ringwall, A.; Borgatti, A.; Kraska, K.; Thomson, C. B.; Cahalane, A. K.; Murray, R. L.; Kisseberth, W. C.; Camps-Palau, M. A.; Floch, F.; Beaudu-Lange, C.; Klajer-Peres, A.; Keravel, O.; Fribourg-Blanc, L. A.; Mazetier, P. C.; Marco, A.; McLeod, M. B.; Portillo, E.; Clark, T. S.; Judd, S.; Feinberg, C. K.; Benitez, M.; Runyan, C.; Hackett, L.; Lafey, S.; Richardson, D.; Vineyard, S.; Campbell, M. T.; Dharajiya, N.; Jensen, T. J.; van den Boom, D.; Diaz, L. A. Jr; Grosu, D. S.; Polk, A.; Marsal, K.; Hicks, S. C.; Lytle, K. M.; Holtvoigt, L.; Chibuk, J.; Chorny, I.; Tsui, D. W. Y.
Article Title: Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study
Abstract: Cancer is the leading cause of death in dogs, yet there are no established screening paradigms for early detection. Liquid biopsy methods that interrogate cancer-derived genomic alterations in cell-free DNA in blood are being adopted for multi-cancer early detection in human medicine and are now available for veterinary use. The CANcer Detection in Dogs (CANDiD) study is an international, multi-center clinical study designed to validate the performance of a novel multi-cancer early detection “liquid biopsy” test developed for noninvasive detection and characterization of cancer in dogs using next-generation sequencing (NGS) of blood-derived DNA; study results are reported here. In total, 1,358 cancer-diagnosed and presumably cancer-free dogs were enrolled in the study, representing the range of breeds, weights, ages, and cancer types seen in routine clinical practice; 1,100 subjects met inclusion criteria for analysis and were used in the validation of the test. Overall, the liquid biopsy test demonstrated a 54.7% (95% CI: 49.3–60.0%) sensitivity and a 98.5% (95% CI: 97.0–99.3%) specificity. For three of the most aggressive canine cancers (lymphoma, hemangiosarcoma, osteosarcoma), the detection rate was 85.4% (95% CI: 78.4–90.9%); and for eight of the most common canine cancers (lymphoma, hemangiosarcoma, osteosarcoma, soft tissue sarcoma, mast cell tumor, mammary gland carcinoma, anal sac adenocarcinoma, malignant melanoma), the detection rate was 61.9% (95% CI: 55.3–68.1%). The test detected cancer signal in patients representing 30 distinct cancer types and provided a Cancer Signal Origin prediction for a subset of patients with hematological malignancies. Furthermore, the test accurately detected cancer signal in four presumably cancer-free subjects before the onset of clinical signs, further supporting the utility of liquid biopsy as an early detection test. Taken together, these findings demonstrate that NGS-based liquid biopsy can offer a novel option for noninvasive multi-cancer detection in dogs. © 2022 Flory et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: osteosarcoma; genetics; animal; animals; angiosarcoma; hemangiosarcoma; tumor marker; dog; dogs; early detection of cancer; blood examination; hematologic tests; procedures; high throughput sequencing; high-throughput nucleotide sequencing; humans; human; liquid biopsy; biomarkers, tumor; early cancer diagnosis
Journal Title: PLoS ONE
Volume: 17
Issue: 4
ISSN: 1932-6203
Publisher: Public Library of Science  
Date Published: 2022-04-26
Start Page: e0266623
Language: English
DOI: 10.1371/journal.pone.0266623
PUBMED: 35471999
PROVIDER: scopus
PMCID: PMC9041869
DOI/URL:
Notes: Article -- Export Date: 1 June 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Luis Alberto Diaz
    148 Diaz